Physician profile
Keri L Holyoak
NPI 1578578357
$438,406.37
in general payments reported to CMS, 2019-2025
30 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $39K · 2023: $85K · 2024: $140K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $185K · Consulting Fee: $100K · Travel and Lodging: $60K · Food and Beverage: $16K · Education: $11K · Honoraria: $8,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $184,537.95 |
| Consulting Fee | $99,538.25 |
| Travel and Lodging | $60,053.69 |
| Food and Beverage | $16,103.00 |
| Education | $11,354.23 |
| Honoraria | $8,080.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $103,343.42 | 2021-2025 | Dupixent |
| Genzyme Corporation | $85,398.77 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $75,821.90 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $46,671.71 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $35,800.98 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $25,808.02 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $25,139.48 | 2021-2025 | |
| Incyte Corporation | $12,771.29 | 2021-2025 | Opzelura |
| Organon LLC | $9,557.48 | 2025 | Vtama |
| Kowa Pharmaceuticals America, INC. | $4,297.60 | 2025 | Zoryve |
| Ucb, INC. | $4,026.42 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $3,907.82 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $1,893.16 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,513.99 | 2021-2025 | |
| Abbvie INC. | $510.79 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $427.49 | 2021 | |
| Janssen Biotech, INC. | $375.69 | 2022-2025 | Tremfya, Remicade, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $224.94 | 2021-2025 | Cabtreo, Jublia |
| Prugen, INC. Pharmaceuticals | $210.00 | 2021 | |
| Amgen INC. | $183.18 | 2022-2025 | Otezla, Otezla |
| Regeneron Pharmaceuticals, INC. | $151.83 | 2024-2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $113.14 | 2023-2024 | Nuzyra |
| Genentech USA, INC. | $75.00 | 2024 | Xolair |
| Lilly USA, LLC | $72.35 | 2021-2024 | Ebglyss |
| Almirall LLC | $32.18 | 2025 | Seysara |
| Janssen Scientific Affairs, LLC | $23.52 | 2025 | Tremfya |
| Botanix Sb INC | $16.79 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $14.32 | 2021 | |
| Qiagen, LLC | $11.65 | 2021 | |
| Dermira, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Holyoak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.